MOSCOW (RUSSIA) – The RIA news agency cited Russian consumer safety watchdog Rospotrebnadzor as saying on Wednesday that clinical trials of a second potential vaccine against COVID-19, developed by Siberia’s Vector Institute has been completed by Russia.
The institute has finished early-stage human trials, known as Phase II, earlier this month.